AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,660.00GBp
26 Nov 2014
Price Change (% chg)

-16.00p (-0.34%)
Prev Close
4,676.00p
Open
4,657.00p
Day's High
4,682.50p
Day's Low
4,652.50p
Volume
1,646,360
Avg. Vol
2,631,957
52-wk High
4,946.41p
52-wk Low
3,367.07p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.39
Market Cap (Mil.): £59,041.62
Shares Outstanding (Mil.): 1,262.81
Dividend: 53.10
Yield (%): 3.63

Financials

  AZN.L Industry Sector
P/E (TTM): 90.38 38.09 39.03
EPS (TTM): 0.52 -- --
ROI: 2.60 17.96 17.31
ROE: 4.71 18.76 18.22
Search Stocks

BRIEF-Almirall's treatment approved by European Commission

* Says gets authorization from European Commission to sell drug combination of aclidinium + formoterol in European Union (EU)

24 Nov 2014

BRIEF-AstraZeneca's Duaklir Genuair approved in Europe for COPD

* Duaklir  genuair  approved in european union for chronic obstructive pulmonary disease Source text for Eikon: Further company coverage:

24 Nov 2014

Fitch Downgrades AstraZenaca to 'A+'; Outlook Stable

(The following statement was released by the rating agency) LONDON, November 21 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical AstraZeneca PLC's (AstraZeneca) Long-term Issuer Default Rating (IDR) and senior unsecured rating to 'A+' from 'AA-'. The Outlook is Stable. The downgrade reflects near-term pressure on sales and profitability associated with patent expiry of key drugs, at a time when the company is investing in R&D, future growth opportunities and operational efficienc

21 Nov 2014

UPDATE 1-U.S. court denies Ranbaxy's bid to block launch of rival generics

(Adds Endo's launch of generic Valcyte and Dr. Reddy's comment)

20 Nov 2014

U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

Nov 20 - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

20 Nov 2014

New Issue- AstraZeneca prices 750 mln euro 2021 bond

Underlying govt bond over midswaps, equivalent to 63.5 bp

19 Nov 2014

BRIEF-ADDvise Lab Solutions receives order from AstraZeneca of about SEK 2.4 mln

* Says receives order from AstraZeneca of about 2.4 million Swedish crowns

19 Nov 2014

AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer

LONDON - AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. | Video

18 Nov 2014

UPDATE 3-AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer

* Investor day comes 8 days before Pfizer can resume pursuit

18 Nov 2014

Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

MUMBAI - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

18 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks